France-based Coave Therapeutics (formerly Horama SAS) has entered into a licensing deal, giving Théa Open Innovation, an ophthalmology company, rights to co-develop and commercialise a gene therapy for retinitis pigmentosa. ---Subscribe to MedNous to access this article--- Regenerative Medicine Company News Finance, Grants, Deals
